Kennedy Capital Management LLC Boosts Holdings in OrthoPediatrics Corp. (NASDAQ:KIDS)

Kennedy Capital Management LLC lifted its stake in OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 129.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 249,978 shares of the company's stock after buying an additional 141,174 shares during the period. Kennedy Capital Management LLC owned about 1.03% of OrthoPediatrics worth $5,794,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Quarry LP acquired a new position in OrthoPediatrics in the third quarter valued at approximately $25,000. R Squared Ltd acquired a new position in shares of OrthoPediatrics during the 4th quarter worth about $48,000. KLP Kapitalforvaltning AS bought a new position in OrthoPediatrics in the fourth quarter valued at approximately $79,000. BNP Paribas Financial Markets increased its holdings in OrthoPediatrics by 125.1% during the third quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company's stock worth $94,000 after buying an additional 1,929 shares during the last quarter. Finally, AlphaCentric Advisors LLC acquired a new stake in OrthoPediatrics in the 4th quarter valued at about $171,000. 69.05% of the stock is owned by institutional investors.

Insider Buying and Selling at OrthoPediatrics

In related news, CEO David R. Bailey sold 6,620 shares of the company's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $164,573.20. Following the completion of the transaction, the chief executive officer now owns 319,155 shares of the company's stock, valued at approximately $7,934,193.30. This represents a 2.03 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, General Counsel Daniel J. Gerritzen sold 5,310 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $132,006.60. Following the sale, the general counsel now directly owns 110,767 shares of the company's stock, valued at approximately $2,753,667.62. This trade represents a 4.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,732 shares of company stock worth $589,978. Company insiders own 31.80% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on KIDS. Truist Financial reduced their price target on OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Lake Street Capital initiated coverage on OrthoPediatrics in a research note on Monday, April 7th. They set a "buy" rating and a $37.00 target price for the company. Needham & Company LLC reiterated a "buy" rating and issued a $42.00 price objective on shares of OrthoPediatrics in a report on Wednesday, April 9th. Finally, Stifel Nicolaus decreased their price target on OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, March 5th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $37.00.

OrthoPediatrics Price Performance

OrthoPediatrics stock traded up $0.15 during mid-day trading on Thursday, hitting $20.74. 39,602 shares of the company traded hands, compared to its average volume of 198,064. The stock has a fifty day moving average price of $23.94 and a 200-day moving average price of $24.62. The stock has a market cap of $503.59 million, a price-to-earnings ratio of -16.93 and a beta of 1.17. OrthoPediatrics Corp. has a one year low of $20.27 and a one year high of $35.99. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last posted its earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.04. The firm had revenue of $52.67 million for the quarter, compared to analysts' expectations of $51.16 million. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. During the same period in the previous year, the firm earned ($0.23) earnings per share. On average, equities analysts predict that OrthoPediatrics Corp. will post -0.93 earnings per share for the current fiscal year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.